This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Nigella Sativa

Black seed / black cumin / kalonji / habbat al-sawda — Mediterranean and Middle Eastern culinary spice with the strongest cardiometabolic evidence base of any common food herb.

Aliases (9)

NIGELLA SATIVA · Black Seed · Black Cumin · Kalonji · Habbat al-Sawda · Habbatussauda · Hak Jung Chao · Roman Coriander · Fennel Flower

TYPICAL DOSE

1-3 g/day ground seed OR 0

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Nigella Sativa?

Black seed / black cumin / kalonji / habbat al-sawda — Mediterranean and Middle Eastern culinary spice with the strongest cardiometabolic evidence base of any common food herb. Thymoquinone (TQ) is the principal bioactive. 2025 GRADE-assessed meta-analysis of 82 RCTs (n≈5026) shows modest but replicated reductions in LDL, total cholesterol, triglycerides, systolic + diastolic BP, fasting glucose, HbA1c, and BMI. Sahebkar 2016 (PMID 27094948) anchors the BP literature (−3.26/−2.80 mmHg). Bronchodilator + antihistamine activity makes it a credible adjunct for asthma and allergic rhinitis. Dose 1-3 g/day ground seed or 0.5-2.5 mL cold-pressed oil with food. Skip if on warfarin/DOACs, pre-surgery, or pregnant. For Dylan: OPTIONAL-ADD, low priority — no metabolic indication, no allergic baseline, V4 already covers anti-inflammatory load with curcumin + omega-3. Worth keeping in the "if hypertension or pre-diabetes ever shows on bloodwork" hedge pocket.

Research Indications

Most Effective

Thymoquinone (TQ)

24-54% of volatile oil; the principal pharmacologically active constituent

Effective

Thymohydroquinone, dithymoquinone, p-cymene, α-pinene, carvacrol, thymol

minor quinones and terpenes; some have weak independent activity

Investigational

Fixed oil components

linoleic acid (~55%), oleic acid (~24%), palmitic acid (~12%), and other fatty acids; deliver TQ and exert mild anti-inflammatory effects…

Investigational

Alkaloids

nigellicine, nigellidine, nigellimine (minor); some bind α2-adrenergic and opioid receptors weakly in vitro

Investigational

Saponins

α-hederin (anti-tumor in vitro; clinical relevance unclear)

Peptide Interactions

Curcumin:

Synergistic

Both work on NF-κB and Nrf2 pathways; overlapping but not redundant. Combined low-dose anti-inflammatory stack is sensible.

Omega-3 (EPA/DHA):

Synergistic

Complementary anti-inflammatory mechanism (resolvin/protectin pathway). Standard cardiometabolic stack pairing.

Berberine

Synergistic

(in pre-diabetic/T2D users): AMPK activation + complementary glucose-lowering mechanism. Additive but watch for hypoglycemia if on antidiabetic meds.

Garlic

Synergistic

(allicin): Mild additive BP + lipid effects.

Cinnamon:

Synergistic

Mild additive glycemic effect.

Vitamin D3:

Synergistic

Co-factor for the immunomodulatory + anti-inflammatory effect; standard pairing.

Quercetin / luteolin / other flavonoids:

Synergistic

Antihistamine + anti-allergy stack for hay fever season.

Anticoagulants (warfarin, DOACs, heparin):

Avoid

Bleeding risk — hard avoid at supplemental doses.

Dual antiplatelet therapy (aspirin + clopidogrel):

Avoid

Bleeding risk additive.

NSAIDs (chronic high-dose):

Avoid

Mild additive bleeding risk; gastric.

Cyclosporine, tacrolimus, sirolimus:

Avoid

Theoretical CYP3A4 interaction — narrow therapeutic index drugs. Discuss with transplant team.

Insulin / sulfonylureas:

Avoid

Watch for hypoglycemia.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety 6

Side Effects

1GI looseness in first few days — usually resolves in a week. More common with oil than with seed.
2Spicy / warming sensation with raw seed at high doses — culinary, not pathological.
3Mild hypotension at higher doses (>3 g/day, especially in already-normotensive users)
4Allergic contact dermatitis (topical use, rare)
5Mild GI upset persisting beyond first week (suggests dose too high; reduce)
6Possible mild hypoglycemia in combination with anti-diabetic meds

When to Stop

Allergic reaction / anaphylaxis — very rare; most often cross-reactivity in users allergic to other Apiaceae/Ranunculaceae species (the plant is in family Ranunculaceae). Treat first-dose with awareness.
Severe hypotension at high oil doses (>10 mL/day) in hypertensive patients on antihypertensives — additive effect.
Bleeding — anti-platelet activity is mild but real; reports of increased bruising or epistaxis at high chronic doses, especially co-administered with NSAIDs or aspirin.
Hepatotoxicity — extremely rare; isolated case reports at very high oil doses (>15 mL/day) over months. Not a typical-dose concern.
Hypothyroid potentiation — at 2 g/day in Hashimoto trials, TSH normalized. Watch in users already on levothyroxine — dose adjustment may be needed.
First 2 weeks: GI adjustment, allergic reaction risk if first exposure
First 8 weeks (if on antidiabetic meds): Watch for hypoglycemia — additive effect
First 8 weeks (if on antihypertensives): Watch for orthostatic hypotension
Pre-surgery: Discontinue 2 weeks before any planned surgery (anti-platelet effect)
Pregnancy: Avoid in pregnancy. Some animal studies show uterotonic activity at high doses; safety in human pregnancy not established at supplemental doses (culinary doses likely fine but err on caution).
Breastfeeding: Limited data; conservative to avoid supplemental doses, culinary use likely fine.
Anticoagulant users (warfarin, DOACs, dual antiplatelet therapy): Hard avoid at supplemental doses. Culinary spice use likely fine but discuss with prescriber.
Pre-surgery (2-week window): Hard avoid.
Hypoglycemia-prone diabetics on sulfonylureas or insulin: Monitor closely if adding.
Hypotensive at baseline (SBP <105 mmHg): Likely avoid supplemental doses.
Autoimmune disease: Theoretical immune-stimulant concern — some animal data suggest TH1 enhancement. Most clinical evidence in autoimmune contexts (Hashimoto, asthma, rheumatoid) is positive, but for someone with active SLE or MS the immunomodulatory profile warrants caution and clinician discussion.